CDKN2A and non-small cell lung carcinoma: p53, KRAS (Kirsten rat sarcoma viral oncogene) mutations, microsatellite instability, and p16 methylation were found in 56%, 27%, 46%, and 38% of patients with NSCLC, respectively.